ARQT,PHAT Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

Dollar change -0.10
Percentage change -0.98	%

Peers: BMRN ANAB RCUS BCRX CARA CNTA DERM VERU SLNO KZIA

| Held by: XBI IWM VTI VXF IWO IBB SCHA VTWO VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-1.79	Insider Own	12.05%	Shs Outstand	117.05M	Perf Week	9.50%
Market Cap	1.18B	Forward P/E	-	EPS next Y	-0.97	Insider Trans	-2.09%	Shs Float	102.94M	Perf Month	20.57%
Income	-195.53M	PEG	-	EPS next Q	-0.28	Inst Own	102.99%	Short Float	26.96%	Perf Quarter	-4.16%
Sales	138.71M	P/S	8.47	EPS this Y	64.44%	Inst Trans	2.79%	Short Ratio	13.75	Perf Half Y	10.70%
Book/sh	1.34	P/B	7.57	EPS next Y	28.16%	ROA	-53.55%	Short Interest	27.76M	Perf Year	439.36%
Cash/sh	2.86	P/C	3.55	EPS next 5Y	9.80%	ROE	-192.31%	52W Range	1.76 - 13.17	Perf YTD	213.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-48.07%	ROI	-73.92%	52W High	-23.01%	Beta	1.22
Dividend TTM	-	Quick Ratio	2.38	Sales past 5Y	303.42%	Gross Margin	89.43%	52W Low	476.14%	ATR (14)	0.63
Dividend Ex-Date	-	Current Ratio	2.46	EPS Y/Y TTM	59.00%	Oper. Margin	-131.16%	RSI (14)	55.71	Volatility	6.25% 6.74%
Employees	296	Debt/Eq	1.33	Sales Y/Y TTM	182.84%	Profit Margin	-140.97%	Recom	1.29	Target Price	19.00
Option/Short	Yes / Yes	LT Debt/Eq	0.69	EPS Q/Q	53.92%	Payout	-	Rel Volume	0.55	Prev Close	10.24
Sales Surprise	18.98%	EPS Surprise	20.88%	Sales Q/Q	17.44%	Earnings	Nov 06 AMC	Avg Volume	2.02M	Price	10.14
SMA20	5.35%	SMA50	6.08%	SMA200	6.57%	Trades		Volume	1,110,712	Change	-0.98%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Nov-20-24 09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average (Zacks)
09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Nov-19-24 09:55AM	Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now (Zacks) +7.00%
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Nov-13-24 08:00AM	Arcutis' ZORYVE (roflumilast) Awarded Best Eczema Treatment by Glamour (GlobeNewswire)
09:55AM	Loading…
Nov-11-24 09:55AM	Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? (Zacks)
Nov-07-24 02:23AM	Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... (GuruFocus.com) +7.66%
Nov-06-24 05:15PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 07:52AM	Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result (GuruFocus.com) +6.65%
Nov-04-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-25-24 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-24-24 08:00AM	Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-23-24 04:00PM	Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference (GlobeNewswire)
Oct-21-24 10:43AM	Health Canada approves Arcutis ZORYVE foam for seborrheic dermatitis (Pharmaceutical Technology)
07:00AM	Loading…
07:00AM	Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older (PR Newswire)
Oct-18-24 08:20AM	Arcutis Announces Health Canada Approval of ZORYVE (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older (GlobeNewswire) -8.11%
Oct-12-24 10:18AM	Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments (Insider Monkey)
Oct-09-24 08:03AM	Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT) (Insider Monkey)
Oct-04-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-25-24 01:00AM	New Data Shows ZORYVE (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types (GlobeNewswire) -5.99%
Sep-24-24 08:00AM	FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over (GlobeNewswire)
Sep-19-24 08:00AM	Arcutis Announces Publication of ZORYVE (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology (GlobeNewswire)
Sep-06-24 01:29AM	Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) (GuruFocus.com)
Sep-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 (GlobeNewswire)
12:01AM	Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-28-24 08:00AM	Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis (GlobeNewswire)
Aug-22-24 08:00AM	Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
01:15PM	Loading…
Aug-15-24 01:15PM	Q2 2024 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.27%
Aug-14-24 09:00PM	CORRECTION Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-24 10:00AM	Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Aug-02-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-24 04:00PM	Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire) -5.86%
Jul-29-24 07:35AM	Arcutis Announces ZORYVE U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. (GlobeNewswire)
07:30AM	Arcutis Launches ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
08:00AM	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over (GlobeNewswire)
Jul-22-24 08:00AM	Arcutis to Host ZORYVE (Roflumilast) Cream 0.15% FDA Approval Call With KOL (GlobeNewswire)
Jul-19-24 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-17-24 09:54AM	Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why (Zacks)
Jul-10-24 01:13PM	Arcutis bags FDA approval for atopic dermatitis cream after delay (Pharmaceutical Technology)
11:23AM	FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years (Benzinga)
07:48AM	AbbVie names new R&D head; Arcutis eczema cream approved (BioPharma Dive)
Jul-09-24 04:53PM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age (GlobeNewswire)
08:00AM	Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis (GlobeNewswire)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.27%
Jul-02-24 07:45AM	Cheap Stocks To Buy: This Microcap Gold Stock Breaks Out (Investor's Business Daily)
Jun-17-24 09:40AM	Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? (Zacks) -7.76%
Jun-14-24 09:55AM	Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet (Zacks) -7.60%
Jun-13-24 06:00AM	Have $5-10? 7 Affordable Stocks That Are About to Breakout. (InvestorPlace) +15.31%
Jun-10-24 02:30PM	Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference (GlobeNewswire)
Jun-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference (GlobeNewswire)
Jun-03-24 08:00AM	Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-31-24 09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
May-20-24 09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 101.09%: Here's is How to Trade (Zacks)
May-16-24 11:23AM	Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise (MT Newswires)
May-15-24 12:54PM	Q1 2024 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.65%
12:03PM	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating (MT Newswires)
09:12AM	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday (MT Newswires)
08:53AM	Sector Update: Health Care (MT Newswires)
08:46AM	Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating (MT Newswires)
08:19AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
04:24AM	Update: Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket (MT Newswires)
03:13AM	Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
May-14-24 08:57PM	ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:53PM	Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump (MT Newswires)
04:00PM	Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Expert Panel Review Further Validates Use of ZORYVE (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology (GlobeNewswire)
May-03-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.98%
Apr-29-24 04:00PM	Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire) -5.24%
Apr-10-24 08:00AM	Arcutis Appoints David Topper as Chief Financial Officer (GlobeNewswire)
Apr-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.49% +10.49%
Apr-01-24 07:00AM	Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream (GlobeNewswire)
Mar-28-24 08:00AM	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-19-24 09:55AM	Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-18-24 09:55AM	Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks)
Mar-11-24 08:00AM	Arcutis Promotes Todd Tucker to Chief Human Resources Officer (GlobeNewswire) -9.96%
Mar-10-24 04:00PM	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-09-24 04:00PM	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction (GlobeNewswire)
Mar-08-24 07:33PM	Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors (Barrons.com) +7.42% -9.96%
Mar-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-24 04:00PM	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -6.97%
08:00AM	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-01-24 09:55AM	Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks) +14.49%
09:40AM	Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-29-24 05:00PM	Arcutis to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
11:33AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 11:30PM	Arcutis Announces Pricing of $150 Million Public Offering (GlobeNewswire)
04:10PM	Arcutis Announces Proposed Public Offering (GlobeNewswire)
04:00PM	Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan (GlobeNewswire)
12:16AM	Q4 2023 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 08:11AM	Arcutis Biotherapeutics Inc (ARQT) Reports Significant Revenue Growth in Q4 2023 (GuruFocus.com) +9.70%
05:50AM	Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burnett Patrick	Officer	Nov 22 '24	Proposed Sale	10.14	16,023	162,515		Nov 22 04:34 PM
Matsuda Masaru	See Remarks	Nov 19 '24	Sale	9.68	1,775	17,190	181,373	Nov 19 07:52 PM
Matsuda Masaru	Officer	Nov 19 '24	Proposed Sale	9.68	1,775	17,190		Nov 19 04:25 PM
Burnett Patrick	See Remarks	Nov 14 '24	Option Exercise	0.00	18,377	0	147,046	Nov 18 07:04 PM
Burnett Patrick	See Remarks	Nov 15 '24	Option Exercise	0.00	100	0	128,769	Nov 18 07:04 PM
Burnett Patrick	See Remarks	Nov 14 '24	Sale	10.29	69,126	711,618	128,669	Nov 18 07:04 PM
Burnett Patrick	See Remarks	Nov 15 '24	Sale	10.03	100	1,003	128,669	Nov 18 07:04 PM
Burnett Patrick	Officer	Nov 15 '24	Proposed Sale	10.03	100	1,003		Nov 15 04:31 PM
Burnett Patrick	Officer	Nov 14 '24	Proposed Sale	10.29	69,126	711,615		Nov 14 04:59 PM
Curran Terrie	Director	Nov 11 '24	Sale	10.85	8,687	94,238	10,139	Nov 13 06:45 PM
Curran Terrie	Director	Nov 11 '24	Proposed Sale	10.85	8,687	94,238		Nov 12 11:34 AM
Matsuda Masaru	See Remarks	Nov 04 '24	Sale	8.68	5,015	43,551	178,273	Nov 05 04:46 PM
Watanabe Todd Franklin	See Remarks	Nov 04 '24	Sale	8.68	13,871	120,459	832,392	Nov 05 04:46 PM
Welgus Howard G.	Director	Nov 01 '24	Sale	8.65	10,000	86,541	171,944	Nov 05 04:46 PM
Burnett Patrick	See Remarks	Nov 04 '24	Sale	8.68	15,441	134,093	179,418	Nov 05 04:45 PM
Watanabe Todd Franklin	Officer	Nov 04 '24	Proposed Sale	8.68	13,871	120,459		Nov 04 04:41 PM
Matsuda Masaru	Officer	Nov 04 '24	Proposed Sale	8.68	5,015	43,551		Nov 04 04:39 PM
Burnett Patrick	Officer	Nov 04 '24	Proposed Sale	8.68	15,441	134,093		Nov 04 04:37 PM
Welgus Howard G.	Director	Nov 01 '24	Proposed Sale	8.65	10,000	86,540		Nov 01 02:51 PM
Welgus Howard G.	Director	Oct 01 '24	Sale	9.26	10,000	92,616	181,944	Oct 03 04:55 PM
Edwards Larry Todd	SVP Chief Commercial Officer	Oct 02 '24	Sale	10.01	3,725	37,295	136,635	Oct 03 04:55 PM
Edwards Larry Todd	Officer	Oct 02 '24	Proposed Sale	10.01	3,725	37,295		Oct 02 04:31 PM
Welgus Howard G.	Director	Oct 01 '24	Proposed Sale	9.26	10,000	92,616		Oct 01 03:32 PM
Topper David Joseph	Chief Financial Officer	Sep 24 '24	Sale	9.48	11,626	110,264	158,374	Sep 25 09:42 PM
Topper David Joseph	Officer	Sep 24 '24	Proposed Sale	9.48	11,626	110,264		Sep 24 03:51 PM
Welgus Howard G.	Director	Sep 03 '24	Sale	10.77	10,000	107,695	191,944	Sep 05 05:56 PM
Welgus Howard G.	Director	Sep 03 '24	Proposed Sale	10.77	10,000	107,695		Sep 03 01:37 PM
Burnett Patrick	See Remarks	Aug 19 '24	Sale	8.29	1,728	14,318	194,859	Aug 21 04:39 PM
Burnett Patrick	Officer	Aug 19 '24	Proposed Sale	8.29	1,728	14,318		Aug 19 05:43 PM
Matsuda Masaru	See Remarks	Aug 02 '24	Sale	9.02	5,220	47,064	183,288	Aug 05 04:37 PM
Burnett Patrick	See Remarks	Aug 02 '24	Sale	9.02	13,206	119,106	196,587	Aug 05 04:37 PM
Watanabe Todd Franklin	See Remarks	Aug 02 '24	Sale	9.02	14,487	130,648	846,263	Aug 05 04:37 PM
Welgus Howard G.	Director	Aug 01 '24	Option Exercise	1.68	6,614	11,115	186,953	Aug 05 04:37 PM
Welgus Howard G.	Director	Aug 01 '24	Sale	9.87	10,000	98,696	176,953	Aug 05 04:37 PM
Matsuda Masaru	Officer	Aug 02 '24	Proposed Sale	9.02	5,220	47,063		Aug 02 04:22 PM
Burnett Patrick	Officer	Aug 01 '24	Proposed Sale	9.14	13,026	119,105		Aug 02 04:20 PM
Watanabe Todd Franklin	Officer	Aug 02 '24	Proposed Sale	9.02	14,487	130,648		Aug 02 04:19 PM
Welgus Howard G.	Director	Aug 01 '24	Proposed Sale	9.87	10,000	98,696		Aug 01 04:45 PM
Welgus Howard G.	Director	Jul 01 '24	Option Exercise	1.68	10,000	16,806	190,339	Jul 02 07:13 PM
Welgus Howard G.	Director	Jul 01 '24	Sale	9.31	10,000	93,141	180,339	Jul 02 07:13 PM
Welgus Howard G.	Director	Jun 04 '24	Option Exercise	1.68	10,000	16,806	180,200	Jun 06 04:15 PM
Welgus Howard G.	Director	Jun 04 '24	Sale	8.01	10,000	80,092	170,200	Jun 06 04:15 PM
Burnett Patrick	See Remarks	May 30 '24	Option Exercise	0.00	23,000	0	232,793	May 31 04:50 PM
Burnett Patrick	See Remarks	May 29 '24	Sale	8.72	49,952	435,387	209,793	May 31 04:50 PM
Burnett Patrick	See Remarks	May 30 '24	Sale	8.75	23,000	201,319	209,793	May 31 04:50 PM
Matsuda Masaru	See Remark	May 28 '24	Sale	9.01	1,775	15,988	188,508	May 29 07:38 PM
Edwards Larry Todd	SVP Chief Commercial Officer	May 17 '24	Sale	8.98	7,640	68,582	140,360	May 20 05:12 PM
Moore Matthew Richard	SVP and Chief Business Officer	May 02 '24	Sale	8.74	4,681	40,902	145,505	May 03 04:29 PM
Watanabe Todd Franklin	See Remarks	May 02 '24	Sale	8.74	13,783	120,433	860,750	May 03 04:22 PM
Matsuda Masaru	See Remark	May 02 '24	Sale	8.74	5,016	43,829	185,408	May 03 04:22 PM
Burnett Patrick	See Remarks	May 02 '24	Sale	8.74	9,555	83,490	259,745	May 03 04:22 PM
Matsuda Masaru	See Remark	Mar 04 '24	Sale	11.12	3,760	41,816	190,424	Mar 06 05:14 PM
Burnett Patrick	See Remarks	Mar 04 '24	Sale	11.12	4,782	53,182	269,300	Mar 06 05:12 PM
Watanabe Todd Franklin	See Remarks	Mar 04 '24	Sale	11.12	14,903	165,739	874,533	Mar 06 05:09 PM
Moore Matthew Richard	SVP and Chief Business Officer	Mar 04 '24	Sale	11.12	3,468	38,568	146,020	Mar 06 05:08 PM
Heron Patrick J	Director	Mar 04 '24	Buy	9.50	21,052	199,994	8,785,284	Mar 06 04:28 PM
Watanabe Todd Franklin	See Remarks	Feb 28 '24	Sale	10.60	2,465	26,129	889,436	Mar 01 04:11 PM
Burnett Patrick	See Remarks	Jan 02 '24	Sale	3.54	1,325	4,692	57,032	Jan 03 05:30 PM
Watanabe Todd Franklin	See Remarks	Dec 01 '23	Option Exercise	1.68	59,525	100,038	513,682	Dec 01 08:51 PM

Dollar change -0.11
Percentage change -1.16	%

PHAT Phathom Pharmaceuticals Inc daily Stock Chart

Peers: NBIX BPMC AXSM BTAI ACAD VKTX MDGL PTGX RDUS XENE

| Held by: VTI VXF IWM SURI VTWO IWN VHT IBB DWAS SCHA

Index	RUT	P/E	-	EPS (ttm)	-5.69	Insider Own	49.04%	Shs Outstand	57.97M	Perf Week	6.38%
Market Cap	631.21M	Forward P/E	-	EPS next Y	-4.10	Insider Trans	-0.15%	Shs Float	34.85M	Perf Month	-42.38%
Income	-339.44M	PEG	-	EPS next Q	-1.20	Inst Own	69.14%	Short Float	50.07%	Perf Quarter	-33.00%
Sales	26.27M	P/S	24.03	EPS this Y	-38.36%	Inst Trans	47.52%	Short Ratio	13.04	Perf Half Y	-11.05%
Book/sh	-2.74	P/B	-	EPS next Y	24.54%	ROA	-108.79%	Short Interest	17.45M	Perf Year	33.62%
Cash/sh	4.95	P/C	1.89	EPS next 5Y	-	ROE	-	52W Range	6.07 - 19.71	Perf YTD	2.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-137.06%	ROI	-109.14%	52W High	-52.61%	Beta	0.62
Dividend TTM	-	Quick Ratio	5.68	Sales past 5Y	0.00%	Gross Margin	82.83%	52W Low	54.00%	ATR (14)	1.36
Dividend Ex-Date	-	Current Ratio	5.73	EPS Y/Y TTM	-48.61%	Oper. Margin	-1096.02%	RSI (14)	30.50	Volatility	10.45% 12.07%
Employees	452	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-1292.14%	Recom	1.25	Target Price	25.29
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-73.87%	Payout	-	Rel Volume	0.92	Prev Close	9.45
Sales Surprise	29.69%	EPS Surprise	10.12%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	1.34M	Price	9.34
SMA20	-31.87%	SMA50	-40.33%	SMA200	-23.43%	Trades		Volume	1,224,797	Change	-1.16%

Date	Action	Analyst	Rating Change	Price Target Change
May-03-24	Initiated	Stifel	Buy	$24
Jan-05-24	Reiterated	Needham	Buy	$23 → $26
Aug-09-23	Initiated	H.C. Wainwright	Buy	$28
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy	$21
Oct-21-22	Initiated	Jefferies	Buy	$16
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral	$40 → $48
Feb-17-21	Initiated	BMO Capital Markets	Outperform	$63
Feb-02-21	Initiated	Guggenheim	Buy	$60
Jun-26-20	Downgrade	Goldman	Neutral → Sell	$34
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Needham	Buy	$40
Nov-19-19	Initiated	Jefferies	Buy	$32
Nov-19-19	Initiated	Goldman	Neutral	$32

Show Previous Ratings

Nov-19-24 12:00PM	Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know (Zacks) +5.40%
Nov-08-24 06:02AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -8.86%
Nov-07-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-24 07:21AM	Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
08:00AM	Loading…
Nov-04-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-24 08:00AM	Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 (GlobeNewswire) +8.29%
Oct-27-24 12:00PM	Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting (GlobeNewswire)
Aug-29-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-19-24 08:00AM	Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Aug-08-24 09:20AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.70%
08:00AM	Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients (GlobeNewswire)
Jul-29-24 07:59AM	Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults (GlobeNewswire) -7.68%
07:00AM	Loading…
Jun-09-24 07:00AM	Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now (InvestorPlace)
Jun-07-24 06:17AM	Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze (InvestorPlace) +9.50%
May-28-24 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-24 08:00AM	Phathom Pharmaceuticals to Present VOQUEZNA (vonoprazan) Data at DDW 2024 Annual Meeting (GlobeNewswire)
May-13-24 11:02AM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 08:00AM	The 3 Best Healthcare Stocks to Buy in May 2024 (InvestorPlace) -5.60%
May-09-24 09:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 08:02AM	Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target (MT Newswires)
Apr-29-24 08:00AM	Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-22-24 03:30AM	SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT (PR Newswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com) -5.38%
11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-03-24 08:00AM	Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Mar-26-24 08:00AM	Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, VOQUEZNA Can Kick Some Acid (GlobeNewswire)
Mar-08-24 03:05PM	Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:57AM	Q4 2023 Phathom Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 01:51PM	PHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -6.58%
01:38PM	Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ... (GuruFocus.com)
08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 08:00AM	Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024 (GlobeNewswire)
Feb-13-24 08:00AM	Phathom Pharmaceuticals Announces VOQUEZNA (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients (GlobeNewswire)
Jan-31-24 08:00AM	Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-14-23 08:00AM	Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital (GlobeNewswire) +7.98%
Dec-06-23 08:00AM	Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD (GlobeNewswire) -5.36%
Nov-28-23 08:00AM	Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn (GlobeNewswire)
Nov-09-23 09:34AM	Phathom Pharmaceuticals Inc (PHAT) Reports Q3 2023 Financial Results (GuruFocus.com)
08:00AM	Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates (GlobeNewswire)
Nov-01-23 05:00PM	Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults (GlobeNewswire) -16.96%
Oct-30-23 08:00AM	Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA TRIPLE PAK (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA DUAL PAK (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults (GlobeNewswire)
Oct-25-23 08:01AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 08:01AM	Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD (GlobeNewswire)
Sep-05-23 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.27%
Aug-21-23 08:00AM	Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application (GlobeNewswire)
Aug-10-23 08:01AM	Phathom Pharmaceuticals Reports Second Quarter 2023 Results (GlobeNewswire)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly)
Aug-07-23 02:34PM	3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now (InvestorPlace)
Jul-14-23 04:40PM	These 2 Biotech Stocks Are Most Likely to Be Acquired, Says Needham and They Have Over 60% Upside Potential (TipRanks)
Jul-10-23 08:26AM	Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies (Zacks)
Jul-07-23 08:38AM	3 Top Breakout Stocks Worth a Buy for Attractive Returns (Zacks)
06:52AM	Pleasing Signs As A Number Of Insiders Buy Phathom Pharmaceuticals Stock (Simply Wall St.)
Jun-12-23 08:01AM	Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD (GlobeNewswire)
Jun-09-23 04:01PM	Phathom Pharmaceuticals Announces Closing of Underwriters Option to Purchase Additional Shares in Connection with Public Offering of Common Stock (GlobeNewswire) +5.61%
Jun-01-23 09:55AM	Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect? (Zacks)
08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-27-23 09:07AM	Institutional owners may ignore Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) recent US$66m market cap decline as longer-term profits stay in the green (Simply Wall St.)
May-26-23 09:55AM	Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
May-25-23 09:55AM	Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross? (Zacks)
May-23-23 07:41PM	Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.41%
04:01PM	Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:00PM	Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA (GlobeNewswire)
May-10-23 08:00AM	Phathom Pharmaceuticals Reports First Quarter 2023 Results (GlobeNewswire)
May-09-23 08:00AM	Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023 (GlobeNewswire)
Apr-12-23 08:00AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.32%
07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research)
Apr-10-23 06:44AM	Daily Vickers Top Buyers & Sellers for 04/10/2023 (Argus Research)
Apr-05-23 08:35AM	Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update (Zacks) -9.51%
Apr-04-23 08:00AM	Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch (GlobeNewswire) +8.42%
Mar-27-23 09:55AM	Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock Now (Zacks) +7.92%
Mar-07-23 12:00PM	All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy (Zacks) -5.54%
Feb-28-23 08:00AM	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) -11.75%
Feb-10-23 08:53AM	Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data (Benzinga) -29.67%
07:59AM	Phathoms stock falls after receiving FDA letters (MarketWatch)
Feb-09-23 04:01PM	Phathom Pharmaceuticals Provides Regulatory Updates (GlobeNewswire)
Jan-28-23 01:58PM	Why Shares of Phathom Pharmaceutical Jumped This Week (Motley Fool)
Jan-24-23 09:02AM	Great news for Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Insiders acquired stock in large numbers last year (Simply Wall St.) +9.84%
Jan-13-23 06:56AM	Daily Vickers Top Buyers & Sellers for 01/13/2023 (Argus Research) +12.06%
Jan-08-23 06:00PM	Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) (GlobeNewswire)
Jan-06-23 05:02AM	The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax (Zacks)
Jan-05-23 11:31AM	Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More (Zacks) -6.66%
Jan-04-23 09:17AM	FDA Issues No Action Notice For Phathom Pharma's Investigational Candidate, Shares Plunge (Benzinga) -31.11%
Jan-03-23 04:01PM	Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis (GlobeNewswire) +6.86%
Nov-08-22 05:00PM	Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -7.55%
Nov-03-22 08:30AM	Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire)
Nov-01-22 08:00AM	Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement (GlobeNewswire)
Oct-24-22 08:00AM	Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD) (GlobeNewswire)
Oct-23-22 12:01PM	Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting (GlobeNewswire)
Oct-18-22 08:00AM	Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting (GlobeNewswire)
Sep-26-22 08:00AM	Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors (GlobeNewswire)
Sep-07-22 08:15AM	Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-17-22 09:16AM	As Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) hits US$444m market cap, insiders may be dismayed about not purchasing higher quantities (Simply Wall St.)
Aug-02-22 08:00AM	Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -28.78%
Jun-01-22 08:15AM	Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-25-22 08:00AM	Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis (GlobeNewswire) -5.25%

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nabulsi Azmi	Chief Operating Officer	Jul 15 '24	Sale	11.72	10,901	127,760	240,421	Jul 17 02:52 PM
Henderson Molly	CFO and CBO	Jul 15 '24	Sale	11.72	4,325	50,689	99,447	Jul 17 02:51 PM
Curran Terrie	President and Chief Executive	Jul 15 '24	Sale	11.72	33,848	396,699	377,734	Jul 17 02:50 PM
Henderson Molly	CFO and CBO	Apr 08 '24	Sale	11.10	3,435	38,128	95,263	Apr 10 04:30 PM
Curran Terrie	President and Chief Executive	Mar 22 '24	Sale	9.11	16,851	153,513	410,784	Mar 26 04:05 PM
TAKEDA PHARMACEUTICAL CO LTD	10% Owner	Jan 24 '24	Sale	8.10	3,703,703	29,999,994	3,755,583	Jan 25 06:13 AM
Henderson Molly	CFO and CBO	Jan 19 '24	Sale	7.75	6,307	48,900	98,698	Jan 22 08:22 PM

ARQT

Arcutis Biotherapeutics Inc

PHAT

Phathom Pharmaceuticals Inc

Upgrade your FINVIZ experience